

Sun's 2QFY26 EBITDA was ahead of the street and our estimates (by ~12%), on the back of a marginally higher gross margin and lower R&D spend. The reported EBITDA margin was again at a multi-quarter high; excluding forex gain, EBITDA was marginally ahead of expectations. The topline surprise was primarily driven by a strong beat in EM + the RoW (no one-offs, per the management), with US and domestic sales being broadly in line. We believe that 2Q performance should put to rest concerns about sustainability of Sun's double-digit domestic growth, given the scale of its domestic business (9th consecutive quarter of double-digit growth). While we admit that the lower R&D spend (which, in line with our earlier expectations, will be at the lower-end of the guidance for FY26) and forex gain have helped Sun well exceed the street's margin expectations over the last 2 quarters, Sun equally deserves credit for gross margin defense at elevated levels (which, as we have been arguing in the past, is a structural driver, given that branded share in the overall mix will continue to increase). Pessimism around specialty ramp-up should get addressed as the base specialty business continues to scale up across markets (US and excl US); Leqselvi further widens access (refer to our note), Unloxcyt is launched in 2HFY26, and Ilumya receives an approval for Psoriatic Arthritis (2HFY27). Sun's specialty portfolio will also benefit from favorable seasonality in 2HFY26. We broadly maintain our earnings estimates, and retain BUY with an unchanged TP of Rs2,000.

US and domestic sales broadly in line; EM and RoW sales ahead of estimates

Global specialty sales were up 16% YoY to USD333mn, in line with our estimate. US sales (base business as well as gRevlimid sales) were in line with expectations, with gRevlimid sales remaining flat QoQ. Domestic formulations growth (at 11% YoY vs our estimate of 9% YoY) was marginally ahead of our expectations. EM sales delivered a meaningful beat, with growth being driven by key markets including South Africa and Brazil. The RoW's outperformance was aided by growth in the generic as well as specialty portfolio.

KTAs from the earnings call

1) Ilumya has now been commercialized in 35 markets, with the product being launched in some of these markets over the last one year. 2) US specialty sales exceeded generic sales for the first time in 2Q. 3) New generic entrants in Restasis will not have an impact on Cequa's growth trajectory. 4) Leqselvi has already started seeing paid prescriptions in the commercial channel. 5) Odomzo has more than 50% share within Hedgehog inhibitors, among dermatologists in the US and Europe. 6) Salesforce for Unloxcyt is in place; costs linked to specialty salesforce, marketing, and patient support programs will continue in FY27. Sun is in the process of compiling the dossier for Unloxcyt in Europe. 7) R&D spend will be at the lower-end of the 6-8% guidance for FY26. Specialty R&D accounted for ~38% of the total R&D spend in 2Q. 8) Sun Pharma will launch Semaglutide in the first wave in India, post the innovator's loss of exclusivity.

Target Price – 12M	Sep-26
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	18.3

Stock Data	SUNP IN
52-week High (Rs)	1,910
52-week Low (Rs)	1,547
Shares outstanding (mn)	2,399.3
Market-cap (Rs bn)	4,055
Market-cap (USD mn)	45,735
Net-debt, FY26E (Rs mn)	(250,462.5)
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	3,931.5
ADTV-3M (USD mn)	44.3
Free float (%)	45.5
Nifty-50	25,597.7
INR/USD	88.7


Shareholding, Sep-25

Promoters (%)	54.5
FPIs/MFs (%)	16.5/20.2

Price Performance

(%)	1M	3M	12M
Absolute	3.6	2.9	(6.6)
Rel. to Nifty	0.8	(0.6)	(12.4)

1-Year share price trend (Rs)



Sun Pharma: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	484,968	525,784	569,164	630,340	699,267
EBITDA	130,231	152,717	162,923	187,211	212,927
Adj. PAT	100,706	119,844	112,066	131,607	153,042
Adj. EPS (Rs)	42.0	50.0	46.7	54.9	63.8
EBITDA margin (%)	26.9	29.0	28.6	29.7	30.5
EBITDA growth (%)	11.8	17.3	6.7	14.9	13.7
Adj. EPS growth (%)	16.5	19.0	(6.5)	17.4	16.3
RoE (%)	16.8	17.6	14.8	15.9	16.8
RoIC (%)	18.1	21.2	19.6	21.6	24.0
P/E (x)	40.3	33.8	36.2	30.8	26.5
EV/EBITDA (x)	29.9	25.5	23.9	20.8	18.3
P/B (x)	6.4	5.6	5.1	4.7	4.2
FCFF yield (%)	2.7	3.1	1.8	3.0	3.4

Source: Company, Emkay Research

Shashank Krishnakumar

shashank.krishnakumar@emkayglobal.com
+91-22-66242466

Bhavya Gandhi

bhavya.gandhi@emkayglobal.com
+91-22-66242409

Mohd Suheb Alam

suheb.alam@emkayglobal.com
+91 022 66242413

Exhibit 1: 2QFY26 Earnings Snapshot

Sun Pharma's P&L (Rs mn)	2QFY25A	2QFY26A	YoY chg	2QFY26E	Delta vs Emkay Est	2QFY26 (consensus)	Delta vs consensus	1QFY26A	QoQ chg
Total sales	1,32,642	1,44,052	9%	1,41,340	2%			1,37,861	4%
Other op income	272	731	169%	1,394	-48%			653	12%
Total revenue from operations	1,32,914	1,44,783	9%	1,42,734	1%	1,42,448	2%	1,38,514	5%
Raw material	26,942	29,827	11%	29,546	1%			28,148	6%
Gross Profit	1,05,972	1,14,956	8%	1,13,188	2%			1,10,366	4%
- Gross Margin	79.7%	79.4%	-33bps	79.3%	10bps			79.7%	-28bps
Staff costs	24,777	27,648	12%	28,717	-4%			28,017	-1%
Other expenses	41,805	42,037	1%	43,543	-3%			39,333	7%
EBITDA	39,390	45,271	15%	40,928	11%	40,256	12%	43,017	5%
- EBITDA Margin	29.6%	31.3%	163bps	28.7%	259bps	28.3%	301bps	31.1%	21bps
Other income	3,540	4,699	33%	4,900	-4%			4,645	1%
Finance Costs	692	999	44%	423	136%			748	34%
Depreciation	6,259	7,295	17%	7,337	-1%			7,006	4%
Profit Before Tax (PBT)	35,979	41,676	16%	38,068	9%			39,908	4%
Tax	5,672	10,305	82%	8,828	17%			9,707	6%
- Tax rate	15.8%	24.7%	896bps	23.2%	154bps			24.3%	40bps
Minority Interest and JVs	(95)	191		87				240	
Exceptional income (expense)	-	-		-				(7,175)	
Reported Net Profit	30,402	31,180	3%	29,153	7%			22,786	37%
Reported EPS (Rs)	12.7	13.0	3%	12.2	7%			9.5	37%
Net Profit - Adjusted	30,402	31,180	3%	29,153	7%	28,811	8%	29,961	4%
EPS (Rs) - Adjusted	12.7	13.0	3%	12.2	7%			12.5	4%

% Cost Ratios	2QFY25A	2QFY26A	YoY chg	2QFY26E	Delta vs Emkay Est	1QFY26A	QoQ chg
Raw Materials	20.3	20.6	33bps	20.7	-10bps	20.3	28bps
Staff Cost	18.6	19.1	45bps	20.1	-102bps	20.2	-113bps
Other expenses	31.5	29.0	-242bps	30.5	-147bps	28.4	64bps

Sales Break-up	2QFY25A	2QFY26A	YoY chg	2QFY26E	Delta vs Emkay Est	1QFY26A	QoQ chg
Domestic Formulations	42,652	47,348	11%	46,490	2%	47,211	0%
US	43,274	43,288	0%	43,032	1%	40,452	7%
Emerging Markets	24,519	28,367	16%	25,858	10%	25,531	11%
RoW Formulations	16,633	20,415	23%	19,421	5%	18,736	9%
APIs	5,338	4,299	-19%	6,006	-28%	5,404	-20%
Others	226	336	48%	534	-37%	527	-36%
Total sales	1,32,642	1,44,052	9%	1,41,340	2%	1,37,861	4%

Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions)

Exhibit 2: Estimate Changes

Figures in Rs mn	FY26E			FY27E			FY28E		
	Old	New	change %	Old	New	change %	Old	New	change %
Domestic formulations	1,88,691	1,89,030	0%	2,11,334	2,11,713	0%	2,34,581	2,35,002	0%
% of total revenue	33.2%	33.2%		33.5%	33.6%		33.6%	33.6%	
US formulations	1,69,777	1,69,777	0%	1,87,322	1,87,322	0%	2,09,870	2,09,870	0%
% of total revenue	29.8%	29.8%		29.7%	29.7%		30.0%	30.0%	
EM + ROW formulations	1,80,103	1,83,701	2%	1,97,089	2,01,421	2%	2,15,704	2,20,868	2%
% of total revenue	31.7%	32.3%		31.3%	32.0%		30.9%	31.6%	
API	23,421	21,292	-9%	25,998	23,634	-9%	28,858	26,234	-9%
% of total revenue	4.1%	3.7%		4.1%	3.7%		4.1%	3.8%	
Net sales	5,64,120	5,65,672	0%	6,24,402	6,26,150	0%	6,92,336	6,94,239	0%
Total income	5,68,955	5,69,164	0%	6,29,962	6,30,340	0%	6,98,730	6,99,267	0%
Gross profit	4,52,888	4,52,912	0%	5,03,969	5,04,272	0%	5,60,382	5,60,812	0%
% margin	79.6%	79.6%		80.0%	80.0%		80.2%	80.2%	
EBITDA	1,57,600	1,62,923	3%	1,83,634	1,87,211	2%	2,10,667	2,12,927	1%
% margin	27.7%	28.6%		29.2%	29.7%		30.2%	30.5%	
PAT	1,11,121	1,12,066	1%	1,31,463	1,31,607	0%	1,52,786	1,53,042	0%
EPS (Rs)	46.3	46.7	1%	54.8	54.9	0%	63.7	63.8	0%

Source: Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

Sun Pharma: Consolidated Financials and Valuations

Profit & Loss

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	484,968	525,784	569,164	630,340	699,267
Revenue growth (%)	10.5	8.4	8.3	10.7	10.9
EBITDA	130,231	152,717	162,923	187,211	212,927
EBITDA growth (%)	11.8	17.3	6.7	14.9	13.7
Depreciation & Amortization	25,566	25,754	29,483	31,517	33,565
EBIT	104,664	126,963	133,440	155,694	179,362
EBIT growth (%)	14.8	21.3	5.1	16.7	15.2
Other operating income	7,384	5,372	3,492	4,190	5,028
Other income	13,542	19,650	19,352	22,062	25,174
Financial expense	2,385	2,314	3,300	3,537	2,112
PBT	115,821	144,300	149,492	174,219	202,424
Extraordinary items	(4,943)	(10,553)	(7,175)	0	0
Taxes	14,395	23,946	36,625	41,813	48,582
Minority interest	(721)	(511)	(800)	(800)	(800)
Income from JV/Associates	-	-	-	-	-
Reported PAT	95,763	109,290	104,891	131,607	153,042
PAT growth (%)	13.0	14.1	(4.0)	25.5	16.3
Adjusted PAT	100,706	119,844	112,066	131,607	153,042
Diluted EPS (Rs)	42.0	50.0	46.7	54.9	63.8
Diluted EPS growth (%)	16.5	19.0	(6.5)	17.4	16.3
DPS (Rs)	12.1	15.1	19.0	22.5	26.5
Dividend payout (%)	28.8	30.2	40.7	41.0	41.5
EBITDA margin (%)	26.9	29.0	28.6	29.7	30.5
EBIT margin (%)	21.6	24.1	23.4	24.7	25.7
Effective tax rate (%)	12.4	16.6	24.5	24.0	24.0
NOPLAT (pre-IndAS)	91,656	105,894	100,748	118,327	136,315
Shares outstanding (mn)	2,399	2,399	2,399	2,399	2,399

Source: Company, Emkay Research

Cash flows

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	102,280	124,649	130,140	152,157	177,250
Others (non-cash items)	21,459	(16,860)	19,352	22,062	25,174
Taxes paid	(15,694)	(4,768)	(36,625)	(41,813)	(48,582)
Change in NWC	(14,646)	9,633	(10,188)	(11,863)	(13,737)
Operating cash flow	121,350	140,721	135,462	155,597	175,782
Capital expenditure	(15,291)	(20,401)	(67,299)	(37,569)	(41,654)
Acquisition of business	(590)	0	0	0	0
Interest & dividend income	13,542	19,650	19,352	22,062	25,174
Investing cash flow	(6,902)	(53,062)	(67,299)	(37,569)	(41,654)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	(33,522)	(9,761)	24,975	(20,000)	(10,000)
Payment of lease liabilities	0	0	0	0	0
Interest paid	(2,385)	(2,314)	(3,300)	(3,537)	(2,112)
Dividend paid (incl tax)	(29,007)	(36,173)	(45,581)	(53,978)	(63,574)
Others	(2,188)	(30,811)	0	0	0
Financing cash flow	(67,102)	(79,058)	(23,907)	(77,514)	(75,685)
Net chg in Cash	47,346	8,601	44,256	40,514	58,442
OCF	121,350	140,721	135,462	155,597	175,782
Adj. OCF (w/o NWC chg.)	135,996	131,088	145,649	167,460	189,519
FCFF	106,059	120,320	68,163	118,028	134,127
FCFE	117,217	137,656	84,214	136,553	157,189
OCF/EBITDA (%)	93.2	92.1	83.1	83.1	82.6
FCFE/PAT (%)	122.4	126.0	80.3	103.8	102.7
FCFF/NOPLAT (%)	115.7	113.6	67.7	99.7	98.4

Source: Company, Emkay Research

Balance Sheet

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	2,399	2,399	2,399	2,399	2,399
Reserves & Surplus	634,268	719,781	786,266	863,895	953,364
Net worth	636,668	722,180	788,665	866,294	955,763
Minority interests	34,592	2,679	3,479	4,279	5,079
Non-current liab. & prov.	13,880	14,179	14,179	14,179	14,179
Total debt	28,457	18,696	43,671	23,671	13,671
Total liabilities & equity	713,596	757,735	849,995	908,424	988,693
Net tangible fixed assets	101,923	100,359	102,147	105,154	109,419
Net intangible assets	130,558	125,503	161,532	164,577	168,401
Net ROU assets	-	-	-	-	-
Capital WIP	11,077	12,343	12,343	12,343	12,343
Goodwill	85,690	89,394	89,394	89,394	89,394
Investments [JV/Associates]	4,426	4,426	4,426	4,426	4,426
Cash & equivalents	191,052	249,877	294,134	334,647	393,089
Current Liab. & Prov.	141,400	163,271	177,143	194,579	214,977
NWC (ex-cash)	274,559	265,225	275,413	287,276	301,013
Total assets	713,596	757,735	849,995	908,424	988,693
Net debt	(162,595)	(231,181)	(250,462)	(310,976)	(379,418)
Capital employed	713,596	757,735	849,995	908,424	988,693
Invested capital	507,041	491,088	539,092	557,007	578,834
BVPS (Rs)	265.4	301.0	328.7	361.1	398.4
Net Debt/Equity (x)	(0.3)	(0.3)	(0.3)	(0.4)	(0.4)
Net Debt/EBITDA (x)	(1.2)	(1.5)	(1.5)	(1.7)	(1.8)
Interest coverage (x)	49.6	63.4	46.3	50.3	96.9
RoCE (%)	17.4	20.3	19.3	20.5	21.9

Source: Company, Emkay Research

Valuations and key Ratios

Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	40.3	33.8	36.2	30.8	26.5
P/CE(x)	32.1	27.8	28.6	24.9	21.7
P/B (x)	6.4	5.6	5.1	4.7	4.2
EV/Sales (x)	8.1	7.5	6.9	6.2	5.6
EV/EBITDA (x)	29.9	25.5	23.9	20.8	18.3
EV/EBIT(x)	37.2	30.7	29.2	25.0	21.7
EV/IC (x)	7.7	7.9	7.2	7.0	6.7
FCFF yield (%)	2.7	3.1	1.8	3.0	3.4
FCFE yield (%)	2.9	3.4	2.1	3.4	3.9
Dividend yield (%)	0.7	0.9	1.1	1.3	1.6
DuPont-RoE split					
Net profit margin (%)	20.8	22.8	19.7	20.9	21.9
Total asset turnover (x)	0.7	0.7	0.7	0.7	0.7
Assets/Equity (x)	1.2	1.1	1.1	1.1	1.0
RoE (%)	16.8	17.6	14.8	15.9	16.8
DuPont-RoIC					
NOPLAT margin (%)	18.9	20.1	17.7	18.8	19.5
IC turnover (x)	1.0	1.1	1.1	1.2	1.2
RoIC (%)	18.1	21.2	19.6	21.6	24.0
Operating metrics					
Core NWC days	206.6	184.1	176.6	166.3	157.1
Total NWC days	206.6	184.1	176.6	166.3	157.1
Fixed asset turnover	2.0	2.3	2.3	2.4	2.6
Opex-to-revenue (%)	51.2	50.5	51.0	50.3	49.8

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions)

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
21-Sep-25	1,656	2,000	Buy	Shashank Krishnakumar
04-Sep-25	1,582	2,000	Buy	Shashank Krishnakumar
01-Aug-25	1,630	2,000	Buy	Shashank Krishnakumar
23-May-25	1,684	2,250	Buy	Shashank Krishnakumar
17-Apr-25	1,752	2,250	Buy	Shashank Krishnakumar
10-Apr-25	1,652	2,400	Buy	Shashank Krishnakumar
06-Mar-25	1,614	2,400	Buy	Shashank Krishnakumar
01-Feb-25	1,742	2,400	Buy	Shashank Krishnakumar
21-Jan-25	1,763	2,400	Buy	Shashank Krishnakumar
13-Jan-25	1,747	2,400	Buy	Shashank Krishnakumar
04-Nov-24	1,809	2,350	Buy	Shashank Krishnakumar
29-Oct-24	1,872	2,350	Buy	Shashank Krishnakumar
27-Oct-24	1,860	2,350	Buy	Shashank Krishnakumar

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 06, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 06, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 06, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)